In A Manufacturing Dispute With FDA, Can A Sponsor Get Help From An Advisory Committee?
Executive Summary
As biosimilars loom on the horizon and a number of innovator biologics face the prospect of having to switch production facilities to accommodate growing demand, the advisory committee review of Eli Lilly & Co.'s application for Sollpura illustrates the challenges that a sponsor may face if it disagrees with FDA about a manufacturing issue.
You may also be interested in...
Can You Still Use Surrogate Markers In A Crowded Drug Class? Sollpura Panel Recommends BMI, Weight Endpoints
The troubles that Alnara Pharmaceuticals has had with its application for Sollpura (liprotamase) for exocrine pancreatic insufficiency signal the challenges that developers of other drugs in crowded classes may face at FDA.
Can You Still Use Surrogate Markers In A Crowded Drug Class? Sollpura Panel Recommends BMI, Weight Endpoints
The troubles that Alnara Pharmaceuticals has had with its application for Sollpura (liprotamase) for exocrine pancreatic insufficiency signal the challenges that developers of other drugs in crowded classes may face at FDA.
Lilly's Solpura Advisory Committee Could Hinge On Manufacturing Issues
Alnara, a Lilly subsidiary, says that its exocrine pancreatic insufficiency treatment is supported by two adequate and well-controlled trials, but FDA says that the product has changed so much that only one of them is relevant - and that one doesn't show strong enough efficacy.